Central redox coenzyme · cellular energy and metabolism
Human evidence for injectable NAD+ is limited. Almost all published clinical studies use oral NAD+/NMN (one systematic review pools 10 controlled trials, ~489 patients). The injectable raises blood NAD+ levels, but raising NAD+ ≠ proven clinical benefit. We position it as a continuous backbone of the mito-stack and longevity protocols, not as a weight-loss piece — there is even a signal that NAD+/NMN may blunt exercise's benefit on glucose. We say it plainly: this is a research compound, not a clinical promise.
NAD+ is the coenzyme that shuttles electrons in every cell. It is a cofactor for the sirtuins and PARPs. Its levels fall with age — hence the idea of replenishing it.
The strongest signal. NAD+ is central to the chain that produces ATP. Research in cellular energy and fatigue.
An obligate cofactor for the sirtuins, enzymes tied to cellular repair and regulation. The longevity rationale.
Some signals in mental clarity and mood. Modest, non-conclusive evidence. Not its primary use.
Levels decline with age. Repletion is a reasonable hypothesis, not a proven clinical benefit in humans.
NAD+ works as a continuous backbone of the "mito-stack." It adds to mitochondrial peptides — not as a weight-loss booster.
NAD+ is a background backbone, not a weight booster. If you want weight loss, the piece is GLP-1, not NAD+.
NAD+ (nicotinamide adenine dinucleotide) is the central redox coenzyme of metabolism: a cofactor for the sirtuins and PARPs, and a key piece in cellular energy production. Its levels fall with age, which is where the idea of replenishing it directly by injection (subcutaneous) comes from — bypassing the low bioavailability of the oral route.
SuperBio Labs NAD+ is supplied as lyophilized powder with verified HPLC ≥99% purity. Each lot ships with an independent Certificate of Analysis confirming identity by LC-MS, content (98–102%), and endotoxin levels (<1.0 EU/mg).
Honest about the evidence level: human clinical evidence is weak for the injectable route — almost all of it comes from studies with oral NAD+/NMN. The injectable raises blood NAD+, but raising NAD+ does not equal a proven clinical benefit. Its best signal is energy and metabolism; cognition and longevity are positioning with thinner evidence. We use it as a continuous backbone of the mito-stack and longevity protocols, not as a weight-loss piece.
Product for informed professional use.
Each order includes everything needed for the cycle. No separate purchases required.
This product meets all five — your batch COA ships with the kit.
Conservative protocol included in the kit. Start low: early on, NAD+ can cause a flush (warmth, flushing) and stinging at the site. Inject slowly. Consult your physician before starting.
Its best signal · support for the cellular energy chain and fatigue.
Background cofactor alongside SS-31 / MOTS-c in mitochondrial protocols.
Rationale from the age-related drop in NAD+ · evidence still developing.
Modest signal in mental clarity · a secondary, not primary, use.
Energy and sleep support in fatigue states · preliminary evidence.
Not a metabolic weight piece · may blunt exercise's effect on glucose.
Far more tolerable than the IV route, but not painless. Most reported:
Flush (warmth, flushing, sometimes nausea) mediated by the GPR109A receptor, especially if you inject fast or at a high dose · stinging at the subcutaneous injection site · both ease by starting low, ramping up slowly, and injecting slowly. There is no established universal protocol. If you take any metabolic or glucose treatment, consult your physician before combining.
| Product | NAD+ |
| CAS Number | 53-84-9 |
| Molecular Weight | 663.4 Da |
| Purity (HPLC) | ≥99% |
| Format | Lyophilized powder |
| Quantity | 1000mg per vial |
| Route | Subcutaneous |
| Endotoxins | <1.0 EU/mg |
| Storage | −20 °C, protected from light |
| Use | For informed professional use |
Reconstitution, dosing, managing the flush, and safety flags for the NAD+ coenzyme.